The Effects of L-Arabinose and D-xylose on Intestinal Sucrase Activity in Man (M192)

October 7, 2013 updated by: AAstrup, University of Copenhagen
The purpose of this study is to investigate the effect of L-arabinose and D-xylose in a sugar-rich drink on intestinal sucrase activity in healthy volunteers by measuring postprandial blood glucose and insulin, and selected intestinal hormonal responses to increasing doses of L-arabinose and D-xylose.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Based on previous scientific results we hypotesize, that pentoses decreases the demand for insulin in metabolizing a given dose of sucrose.

Study Type

Interventional

Enrollment (Actual)

14

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Denmark
      • Frederiksberg, Denmark, DK-1958
        • Institute of Human Nutrition, The Royal Veterinary and Agricultural University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 30 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • healthy males
  • BMI between 18.4-25 kg/m2
  • age between 18 and 30

Exclusion Criteria:

  • donation of blood 3 months before or during the study
  • gastrointestinal disorders, diabetes, hypertension, hyperlipidemia, chronic infectious disease (HIV or hepatitis)
  • smoking
  • consumption of more than 21 alcoholic drinks/week
  • elite athletes
  • on medication

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: 0% pentose
Pure sucrose without pentoses added.
Dietary supplement: Placebo comparator: 0% pentose
14 healthy subjects participated in a randomized double-blinded cross-over study based on four single tests. Sucrose containing drinks were supplemented with two different doses of D-xylose and in addition one dose of L-arabinose was included for comparison with earlier studies. Blood was collected fasting and for 3-h postprandially. Appetite sensations and energy intake were registered. Gastrointestinal symptoms were monitored for 24 hours
Active Comparator: 4% D-xylose
Sucrose drink supplemented with 4% D-xylose
Dietary supplement: Active comparator: 4% D-xylose
Active Comparator: 8% D-xylose
Sucrose drink supplemented with 8% D-xylose
Dietary supplement: Active comparator: 8% D-xylose
Active Comparator: 8% L-arabinose
Sucrose drink supplemented with 8% L-arabinose
Dietary supplement: Active comparator: 8% L-arabinose

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood glucose, insulin, C-peptide and GLP-1
Time Frame: -15, 0, 15, 30, 45, 60, 90, 120, 180 min
Level of glucose, insulin, C-peptide and glucagon-like peptide-1 (GLP-1) over time, the area under the curve (AUC), the peak value and time to peak
-15, 0, 15, 30, 45, 60, 90, 120, 180 min

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Appetite measurements and energy intake
Time Frame: -15, 30, 60, 90, 120, 150 and 180 min
Appetite measurements: area under/over the curve (AUC/AOC), 3-h mean. Energy intake: the ad libitum energy intake at lunch was registered. VAS was used to asses the palatability (appearance, smell, taste, after-taste and overall palatability) of the ad libitum lunch.
-15, 30, 60, 90, 120, 150 and 180 min

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Copenhagen

Collaborators

Danisco

Investigators

  • Study Chair: Jens R Andersen, MD,MPA, Department of Nutrition, Exercise and sports, University of Copenhagen

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2006

Primary Completion (Actual)

January 1, 2007

Study Completion (Actual)

May 1, 2007

Study Registration Dates

First Submitted

August 8, 2013

First Submitted That Met QC Criteria

October 7, 2013

First Posted (Estimate)

October 8, 2013

Study Record Updates

Last Update Posted (Estimate)

October 8, 2013

Last Update Submitted That Met QC Criteria

October 7, 2013

Last Verified

October 1, 2013

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • (KF) 11 324909

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Insulin Resistance

Clinical Trials on Placebo comparator: 0% pentose

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe